Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
1.31(c) 1.25(c) 1.25(c) 1.16(c) 1.08(c) Last
20 151 285 7 330 781 4 247 167 6 394 906 8 845 045 Volume
+29.70% -4.58% 0.00% -7.20% -6.90% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 6,85x
Capi. / Sales2014 3,02x
Capitalization 108 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
02/20 PROTALIX BIOTHERAPEUTICS : Announces Record Date for the 2017 Annual Meeting of ..
02/17 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Regulation FD Disclosur..
02/16 PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
02/15 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Shareholder Director No..
02/15 PROTALIX BIOTHERAPEUTICS, INC. : Shareholder Director Nominations (form 8-K)
02/14 Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of..
02/13 Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium&tra..
02/09 KNIGHT THERAPEUTICS : Plants Small Seed Position In Protalix
01/09 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Results of Operations a..
01/09 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, ..
More news
Sector news : Biotechnology & Medical Research - NEC
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 474%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..142.70%108
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 091
CELLTRION, INC.--.--%10 773
LONZA GROUP AG1.87%10 358
SEATTLE GENETICS, INC.24.12%9 272
More Results